MedTrace Logo

Effects of MET-3 and MET-5 on Gut Microbiome and Metabolic Function in Men and Women With Hypertriglyceridemia

NCT04507971 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-08-11

No results posted yet for this study

Summary

The purpose of this pilot study is to determine the effects of two human microbiome formulations (MET-3 and MET-5) on fasting serum TG concentration.

Conditions

  • Obesity, Metabolically Benign

Interventions

BIOLOGICAL

MET-3

Human microbiome supplementation derived from bacterial strains isolated from fecal matter and grown in a laboratory environment

Sponsors & Collaborators

  • NuBiyota

    lead OTHER

Principal Investigators

  • Thomas Wolever, MD/PhD · INQUIS Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-22
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04507971 on ClinicalTrials.gov